CA3139082A1 - Nouvelles compositions pharmaceutiques et methodes de traitement de troubles mentaux, comportementaux et cognitifs - Google Patents

Nouvelles compositions pharmaceutiques et methodes de traitement de troubles mentaux, comportementaux et cognitifs Download PDF

Info

Publication number
CA3139082A1
CA3139082A1 CA3139082A CA3139082A CA3139082A1 CA 3139082 A1 CA3139082 A1 CA 3139082A1 CA 3139082 A CA3139082 A CA 3139082A CA 3139082 A CA3139082 A CA 3139082A CA 3139082 A1 CA3139082 A1 CA 3139082A1
Authority
CA
Canada
Prior art keywords
azelastine
pharmaceutically acceptable
pharmaceutical composition
disease
donepezil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3139082A
Other languages
English (en)
Inventor
Jianmin Wang
Geping Cui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LA Pharmatech Inc
Original Assignee
LA Pharmatech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LA Pharmatech Inc filed Critical LA Pharmatech Inc
Publication of CA3139082A1 publication Critical patent/CA3139082A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P70/00—Climate change mitigation technologies in the production process for final industrial or consumer products
    • Y02P70/50—Manufacturing or production processes characterised by the final manufactured product

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une composition pharmaceutique contenant les ingrédients thérapeutiquement actifs de l'azélastine ou un sel pharmaceutiquement acceptable de l'azélastine et du donépézil ou de la rivastigmine ou de la galantamine ou un sel pharmaceutiquement acceptable associé. L'invention concerne également une méthode d'utilisation de la composition pharmaceutique pour traiter des patients souffrant de troubles mentaux, comportementaux et cognitifs.
CA3139082A 2019-05-21 2019-05-21 Nouvelles compositions pharmaceutiques et methodes de traitement de troubles mentaux, comportementaux et cognitifs Pending CA3139082A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2019/033359 WO2020236159A1 (fr) 2019-05-21 2019-05-21 Nouvelles compositions pharmaceutiques et méthodes de traitement de troubles mentaux, comportementaux et cognitifs

Publications (1)

Publication Number Publication Date
CA3139082A1 true CA3139082A1 (fr) 2020-11-26

Family

ID=73459142

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3139082A Pending CA3139082A1 (fr) 2019-05-21 2019-05-21 Nouvelles compositions pharmaceutiques et methodes de traitement de troubles mentaux, comportementaux et cognitifs

Country Status (6)

Country Link
EP (1) EP3973586A4 (fr)
JP (1) JP2022539944A (fr)
CN (1) CN114072945A (fr)
AU (1) AU2019446955A1 (fr)
CA (1) CA3139082A1 (fr)
WO (1) WO2020236159A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11318144B2 (en) 2019-04-12 2022-05-03 LA PharmaTech Inc. Compositions and methods for treating Alzheimer's disease and Parkinson's disease
US11351179B1 (en) 2021-08-05 2022-06-07 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of psychiatric disorders
US11389458B2 (en) 2019-04-12 2022-07-19 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating parkinson's and huntington's disease
US11690849B2 (en) 2019-04-12 2023-07-04 LA PharmaTech Inc. Method of treating dementia
US11744833B2 (en) 2019-04-12 2023-09-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of insomnia
US11938139B2 (en) 2019-04-12 2024-03-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10639314B1 (en) 2019-04-30 2020-05-05 LA PharmaTech Inc. Method of treating Alzheimer's disease
US10966989B2 (en) 2019-04-12 2021-04-06 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders
WO2024072049A1 (fr) * 2022-09-26 2024-04-04 주식회사 지투지바이오 Association pharmaceutique contenant du donépézil et de la rivastigmine pour prévenir, soulager ou traiter la démence ou la déficience cognitive et procédé de préparation s'y rapportant

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1298715C (zh) * 2001-03-13 2007-02-07 先灵公司 作为组胺h3拮抗剂的非咪唑化合物
US7491748B2 (en) * 2001-08-09 2009-02-17 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
US7355042B2 (en) * 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
WO2008051599A2 (fr) * 2006-10-27 2008-05-02 Medivation Neurology, Inc. Procédés et combinaison de thérapies pour le traitement de la maladie d'alzheimer
FR2974729B1 (fr) * 2011-05-02 2013-04-19 Servier Lab Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent
SG11201601306QA (en) * 2013-09-09 2016-03-30 Sanofi Sa An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11318144B2 (en) 2019-04-12 2022-05-03 LA PharmaTech Inc. Compositions and methods for treating Alzheimer's disease and Parkinson's disease
US11389458B2 (en) 2019-04-12 2022-07-19 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating parkinson's and huntington's disease
US11690849B2 (en) 2019-04-12 2023-07-04 LA PharmaTech Inc. Method of treating dementia
US11744833B2 (en) 2019-04-12 2023-09-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of insomnia
US11938139B2 (en) 2019-04-12 2024-03-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders
US11351179B1 (en) 2021-08-05 2022-06-07 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of psychiatric disorders

Also Published As

Publication number Publication date
EP3973586A1 (fr) 2022-03-30
CN114072945A (zh) 2022-02-18
AU2019446955A1 (en) 2021-12-23
WO2020236159A1 (fr) 2020-11-26
JP2022539944A (ja) 2022-09-14
EP3973586A4 (fr) 2023-01-11

Similar Documents

Publication Publication Date Title
US10639315B1 (en) Pharmaceutical compositions and methods for treating Alzheimer's disease
US11389458B2 (en) Pharmaceutical compositions and methods for treating parkinson's and huntington's disease
CA3139082A1 (fr) Nouvelles compositions pharmaceutiques et methodes de traitement de troubles mentaux, comportementaux et cognitifs
US10639314B1 (en) Method of treating Alzheimer's disease
JP7365426B2 (ja) 精神障害、行動障害、認知障害を処置するための医薬組成物及び方法
US10966989B2 (en) Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders
US10898493B2 (en) Pharmaceutical compositions and methods for psychiatric symptoms of patients with Alzheimer's disease
US9636316B2 (en) Baclofen and acamprosate based therapy of neurological disorders
US11690849B2 (en) Method of treating dementia
CA3137393A1 (fr) Procede de traitement de troubles mentaux, comportementaux et cognitifs
KR20080068766A (ko) 흥분 및 그 밖의 다른 행동 장애, 특히 알츠하이머 질환과연관된 것을 치료하기 위한 1-아미노사이클로헥산 유도체
WO2021242235A1 (fr) Compositions pharmaceutiques et procédés pour des symptômes psychiatriques de patients atteints de la maladie d'alzheimer et pour des troubles psychiatriques
US20220370443A1 (en) Method of treating alzheimer's disease